# Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

> **NCT01259817** · PHASE2 · COMPLETED · sponsor: **Ronald Hoffman** · enrollment: 135 (actual)

## Conditions studied

- High Risk Polycythemia Vera
- High Risk Essential Thrombocythemia

## Interventions

- **DRUG:** PEGASYS
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT01259817
- **Lead sponsor:** Ronald Hoffman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2017-01-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259817, "Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01259817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*